ERBB2 and breast cancer: Studies including Only Specific BC Molecular Subtypes: Koh et al. [30] showed that in 157 patients with hormone receptor-positive/HER2-negative BC, NLR was an independent prognostic factor for OS (HR = 24.87; 95% CI 3.1–201.3; p = 0.003).